What Wealthy Investors Are Buying

In this edition of Motley Fool Conversations, David Kuo welcomes Elissa Bayer, asset manager at Williams de Broe. They debate dividends, chew over cash, and ponder the prospects for three of Elissa's favorite stocks: AppleBritish American Tobacco, and GlaxoSmithKline, with a few kind words thrown in for Diageo and SABMiller.

Investing is by no means easy in today's uncertain economy. That's why we've published "Top Sectors of 2012" -- our guide to three favorable industries. This free report will be dispatched immediately to your inbox.

Further Motley Fool investment opportunities

The Motley Fool owns shares of Apple and GlaxoSmithKline. Motley Fool newsletter services recommend Apple, Diageo, and GlaxoSmithKline. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (1)

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1943085, ~/Articles/ArticleHandler.aspx, 8/24/2016 8:20:49 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 11 hours ago Sponsored by:
DOW 18,547.30 17.88 0.10%
S&P 500 2,186.90 4.26 0.20%
NASD 5,260.08 15.48 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/23/2016 4:00 PM
AAPL $108.85 Up +0.34 +0.31%
Apple CAPS Rating: ****
DEO $114.81 Up +0.31 +0.27%
Diageo CAPS Rating: *****
GSK $44.41 Up +0.29 +0.66%
GlaxoSmithKline CAPS Rating: ***